LMAT:NASDAQLeMaitre Vascular, Inc. Analysis

LeMaitre Vascular delivered a solid Q1 performance, with revenue climbing 11.2% YoY to $66.55 million and GAAP EPS of $0.68 beating consensus by nearly 3%. The company’s gross margin expanded to over 71% and operating margin sits at a healthy 27%, underscoring strong pricing power and cost control. Technical indicators show the stock hovering near its support level of $95.46, with an RSI of 35 hinting at modest oversold conditions, while the MACD remains bearish, suggesting short‑term downside pressure. Valuation metrics paint a contrasting picture: the market price of $97.75 is well above the DCF‑derived fair value of $56.33 and the PE ratio of 35.9 exceeds the industry average of 27.6, indicating the stock is currently overvalued. Despite this, the dividend yield of 1.02% is supported by a low payout ratio of 31% and ample cash on hand, making the dividend sustainable. The stock’s beta of 0.67 and 30‑day volatility of roughly 36% point to moderate market sensitivity, while increasing volume suggests growing investor interest.
Overall, LeMaitre’s robust fundamentals, expanding margins, and reliable dividend provide a solid foundation, but the premium valuation and bearish short‑term momentum temper enthusiasm. Investors should weigh the upside from continued revenue growth against the risk of a price correction toward intrinsic value, and consider the dividend as a modest income buffer in a volatile environment.